TRDA | Entrada Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	17.52 - 17.94
52 Week Range	10.75 - 20.49
Beta	0.98
Implied Volatility	163.85%
IV Rank	50.26%
Day's Volume	64,565
Average Volume	138,253
Shares Outstanding	37,419,975
Market Cap	670,940,152
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-10-29

Valuation
Profitability
Growth
Health
P/E Ratio	12.45
Forward P/E Ratio	N/A
EPS	1.44
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	168
Country	USA
Website	TRDA

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

TRDA's peers: CNTA, MOLN, PMVP, SVRA, TARS, GLUE, VIGL, THRD, CGEM, EWTX, RLYB, CRNX, IRON, LRMR, PEPG, TYRA, PHVS, GLSH, ELYM, GNTA, OPT, PRDS, BLTE, HLVX, VANI

*Chart delayed

Analyzing fundamentals for TRDA we got that it has weak fundamentals where Valuation is considered to be slightly overvalued, Profitability is wealthy, Growth is desperately bad and Health is passable. For more detailed analysis please see TRDA Fundamentals page.

Watching at TRDA technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on TRDA Technicals page.